Engineered Tissue Solutions

What Engineered Tissue Solutions does

Engineered Tissue Solutions (ETS Wound Care LLC) is a privately-held specialty medical device company headquartered in Rolla, Missouri, and a wholly-owned subsidiary of Heraeus Group, a diversified German family-owned technology company, since the 2021 acquisition. ETS develops and commercializes Mirragen and MirraSurg, the only borate-based bioactive glass wound care matrices on the market and the first FDA-cleared inorganic bioactive glass wound matrices. The technology platform is a synthetic porous scaffold made of borate-based bioactive glass fibers and microspheres composed of natural body elements (Boron, Calcium, Magnesium, Phosphorus) that resorb over 1-3 weeks and support angiogenesis, granulation tissue formation, and re-epithelialization without infection risk or tissue-tracking burdens associated with allograft/xenograft skin substitutes. The product portfolio addresses chronic wound care (diabetic foot ulcers, venous ulcers, pressure ulcers) via Mirragen and surgical/trauma wound care via MirraSurg, with both products backed by multicenter randomized controlled trial evidence showing statistically significant closure rate improvements versus standard of care.

ETS generates revenue through direct medical device product sales of Mirragen and MirraSurg to hospitals, wound care centers, and outpatient clinics in the United States. The go-to-market model combines a direct field sales organization (~24 sales professionals under a VP of Sales) with national GPO contracts at Premier, Inc. (Technology Breakthrough Designation, effective September 2025) and Vizient, Inc. (Innovative Technology contract, May 2024), supplemented by 1099 independent distributor partnerships. Reimbursement support is delivered through a partnership with The Pinnacle Health Group. Pricing is not publicly disclosed and operates through GPO-negotiated terms. Two FDA-cleared products target differentiated segments with strong clinical evidence (73% complete closure vs 42% SOC in 148-patient RCT) and a multi-patent intangible asset base spanning US and European filings.

Name

Engineered Tissue Solutions

Legal name

ETS Wound Care LLC

Website

https://engineeredtissue.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Engineered Tissue Solutions (ETS) is a Heraeus Group subsidiary that develops Mirragen and MirraSurg, the first FDA-cleared borate-based bioactive glass wound care matrices, sold to US hospitals, wound care centers, and outpatient clinics for chronic and surgical wound treatment.

Ownership category

akta.pro rank

Product category

Advanced Wound Care Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA)

Keywords

• Advanced wound care
• Bioactive glass matrices
• Synthetic skin substitutes
• Diabetic foot ulcer treatment
• Surgical wound management

Headquarters

HQ city

Rolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Medical Device Product Sales: ETS generates revenue through the sale of its Mirragen and MirraSurg bioactive glass wound matrices to healthcare providers, hospitals, and wound care centers. Products are sold through direct sales, GPO contracts, and distributor relationships.
2. 1099 Distributor Sales: The company expands market reach through independent 1099 distributor partnerships, where distributors earn commission-based compensation on sales of Mirragen and MirraSurg products.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels10 records

Core offering

Engineered Tissue Solutions manufactures and sells FDA-cleared borate-based bioactive glass fiber wound matrices under the Mirragen and MirraSurg brands. Mirragen is designed for chronic wound care (diabetic foot ulcers, venous and pressure ulcers), while MirraSurg targets surgical and trauma wounds in operating room settings. The synthetic matrices serve as porous scaffolds that support tissue regeneration without the infection risks associated with tissue-based skin substitutes.

Product overview

Engineered Tissue Solutions offers a portfolio of two core bioactive glass wound care products built on proprietary borate-based bioactive glass fiber technology. Mirragen Advanced Wound Matrix serves the chronic wound care market (diabetic foot ulcers, venous ulcers, pressure ulcers), while MirraSurg Wound Matrix is specifically designed for surgical and acute wound applications in the operating room. Both products utilize the same underlying borate-based bioactive glass technology platform but are marketed for different clinical settings and wound types. As synthetic skin substitutes, both products avoid the traditional infection risks associated with tissue-based products and can be stored at room temperature for up to five years.

Differentiator

Problem solved

Functional benefit

Brands

• Mirragen: Borate-based bioactive glass fiber matrix for advanced wound care, designed for treatment of chronic wounds including diabetic foot ulcers, venous ulcers, and pressure ulcers.
• MirraSurg

Products and services

• Mirragen Advanced Wound Matrix Borate-based bioactive glass fiber matrix wound care product that facilitates quality tissue formation for chronic wounds including diabetic foot ulcers, venous ulcers, pressure ulcers, and surgical wounds. Provides a porous scaffold that supports angiogenesis, granulation tissue formation, and re-epithelialization. Stored at room temperature for up to five years with no preparation required.
• MirraSurg Wound Matrix Bioactive glass wound matrix specifically designed for surgical and trauma wounds in the operating room setting. Flexible and formable structure that adapts to three-dimensional soft-tissue defects with zero index wound infections reported in clinical trials. Bioabsorbable with no removal required.

Quantifiable outcome

• 73% complete wound closure at 12 weeks vs 42% SOC (Per Protocol) in Wagner Grade 1 DFUs
• +6 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Premier, Inc.coreGTM or Marketing Partner · 15 September 2025ETS was awarded a national group purchasing agreement and Technology Breakthrough Designation for Reconstructive Skin Grafting Products with Premier, Inc. The agreement (effective September 1, 2025) allows Premier members to access Mirragen and MirraSurg at pre-negotiated pricing. Premier serves approximately two-thirds of all healthcare providers in the U.S. The Breakthrough Technology designation recognizes innovations offering major advantages in patient safety, clinical outcomes, and operational efficiencies.
• TransdiagencoreStrategic or Co-development Partner · 7 August 2025ETS partnered with UK-based precision medicine company Transdiagen to conduct groundbreaking gene expression research in chronic wound healing. This marks the first time any skin substitute (CTP/CAMP) has undergone genomic-level evaluation in a chronic wound environment. Transdiagen will analyze molecular changes in chronic wound tissue through its proprietary gene expression signatures pre- and post-treatment with Mirragen. The study began in Q3 2025 to understand how Mirragen modulates the wound microenvironment and supports tissue regeneration at the genetic level.
• Vizient, Inc.coreGTM or Marketing Partner · 7 May 2024ETS received an Innovative Technology contract from Vizient, the nation's largest provider-driven healthcare performance improvement company. The contract was awarded based on recommendation by hospital experts on Vizient's customer-led councils. Vizient represents a diverse customer base including academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers with portfolio representing more than $140 billion in annual purchasing volume.
• The Pinnacle Health GroupsupportingImplementation/ SI/ Consulting PartnerETS provides reimbursement support through partnership with The Pinnacle Health Group. The partnership offers a Reimbursement Hotline (1.866.369.9290) and Benefit Verification Program to help healthcare providers navigate coding and coverage questions for Mirragen and MirraSurg products.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Smith+Nephew: Smith+Nephew is a large diversified medical device company with a significant Advanced Wound Management division offering skin substitutes, dressings, and negative pressure wound therapy. It competes with ETS in chronic wound care as part of a much broader portfolio and represents a broad incumbent competitor.
• 3M / Solventum: Solventum (spun off from 3M) is a large diversified health care company offering a wound care portfolio including advanced wound dressings and skin management products. It competes with ETS across the chronic and surgical wound care markets as a broad incumbent with established hospital relationships.
• Convatec: Convatec is a global medical products and technologies company specializing in advanced wound care, ostomy, continence, and infusion care. Its wound care portfolio (including InnovaMatrix) competes with Mirragen in chronic wound applications as part of a broader wound care line.
• Mölnlycke Health Care: Mölnlycke is a Swedish medical solutions company with a major wound care division (Mepilex, Mepitel, Avance) including negative pressure wound therapy. It is a broad incumbent competitor in advanced wound care, serving similar hospital and outpatient customers as ETS.
• Coloplast: Coloplast is a Danish multinational with a significant wound and skin care division offering a range of wound dressings and skin substitutes. It competes with ETS in chronic wound care markets through hospital and home health channels globally.

Emerging players

• CorMatrix Cardiovascular: CorMatrix develops ECM-based biomaterials for cardiovascular and soft tissue repair, sharing the regenerative biomaterials space with ETS. While focused on different anatomical applications (cardiac surgery), it is comparable as a niche biomaterials company with overlapping scientific foundations.

Direct peers

• Integra LifeSciences: Integra LifeSciences is a global medical device company with a substantial regenerative tissue technologies portfolio including Integra Dermal Regeneration Template and amniotic tissue products. It competes with ETS in both chronic wound and surgical wound applications and serves similar hospital and wound care customers.
• Organogenesis Holdings: Organogenesis is a leading US-based regenerative medicine company and one of the largest commercializers of skin substitutes and wound care products (Apligraf, Dermagraft, PuraPly, etc.). It is a direct competitor to ETS in the CTP/skin substitute market serving chronic wound and surgical applications, with overlapping hospital and wound care center customers.
• MiMedx: MiMedx is a major competitor in the skin substitute and wound healing market with products such as EpiFix, AmnioFix, and other amniotic membrane-based allografts. It competes directly with Mirragen for hospital formulary placements in chronic wound care, particularly for diabetic foot ulcers and venous leg ulcers.

Others

• Mo-Sci Corporation: Mo-Sci is a specialty glass manufacturer and a sister company within the Heraeus Group family, focused on custom glass and bioactive glass technologies for medical, industrial, and research applications. It is closely related as a co-portfolio company and potential technology enabler for ETS's bioactive glass formulations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/engineeredtissuesolutions
• LinkedInlinkedin.com/company/etswoundcare
• Instagraminstagram.com/engineeredtissuesolutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Engineered Tissue Solutions